APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-14

Price

$134.55

+0.07%

This is the 2026-08-14 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score15.5Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.3xvs 20d avg

Analysis

Apogee Therapeutics (APGE) is trading as a definitive merger arbitrage play following AbbVie's agreement to acquire the company for $135.11 per share in cash. The stock's compressed realized volatility of 1.7% and current price of $134.55 reflect a remarkably tight 0.4% deal spread, which directly triggers our QUIET_STORM and SURGE technical signals. In the current RISK_ON macro regime characterized by ultra-low OAS credit spreads (0.79%) and abundant corporate liquidity, the market is pricing in near-certainty for the deal's closure, eliminating standard directional price discovery.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

M&A Arbitrage Pin: Price action is entirely dominated by the pending $135.11/share all-cash acquisition by AbbVie, anchoring the stock at $134.55.
Macro Tailwinds for M&A: The RISK_ON regime with historically low credit spreads (0.79% OAS) provides an ideal backdrop for deal completion, explaining the ultra-tight 0.4% arbitrage spread.
Signal Alignment: The QUIET_STORM signal perfectly captures the 1.7% realized volatility collapse, while SURGE and ALPHA_MALE reflect the sustained post-announcement plateau and institutional absorption.

← Back to 2026-08-14 View Full APGE History →Yahoo Finance &nearr;